Get started
Author

Wai Meng David Tai

Observed names: W M Tai, W. M. D. Tai, W. M. Tai, W.M. Tai, Wai M. Tai, Wai Meng Tai, Wai Ming Tai, Wai Meng Tai
Observed institutions: National University of Singapore, SingHealth Duke-NUS Academic Medical Centre, Duke-NUS Medical School, University of Colorado Cancer Center, National Cancer Centre Singapore, Kiang Wu Hospital, University of Colorado Anschutz, University of Colorado Denver
ORCID: 0000-0001-8538-9948
Observed ORCID: 0000-0001-8538-9948
OpenAlex ID: A5103201523
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
2025 · Bruno Sangro, Bruno Sangro, et al. · The Lancet · 311
PDF
Comparison of hepatocellular carcinoma in E astern versus W estern populations
2016 · Su Pin Choo, Wan Ling Tan, et al. · Cancer · 264
PDF
Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19
2021 · Chun Chau Lawrence Cheung, Denise Goh, et al. · Gut · 181
PDF
Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).
2020 · Robin Kate Kelley, Bruno Sangro, et al. · Journal of Clinical Oncology · 101
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC)
2016 · W.M. Tai, W.P. Yong, et al. · Annals of Oncology · 60
PDF
Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma
2011 · Hung Huynh, Pierce Kah Hoe Chow, et al. · Journal of Hepatology · 59
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
2016 · Kevin S. Quackenbush, Stacey Bagby, et al. · Oncotarget · 43
Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors.
2013 · Richard Kefford, Wilson H Miller, et al. · Journal of Clinical Oncology · 43
Abstract CT183: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies
2019 · Giuseppe Curigliano, Hans Gelderblom, et al. · Cancer Research · 41
Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model
2013 · J J Arcaroli, K S Quackenbush, et al. · British Journal of Cancer · 41
PDF
A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.
2020 · Wai Meng David Tai, Kelvin Siu Hoong Loke, et al. · Journal of Clinical Oncology · 38
Understanding the genetic basis of gastric cancer: recent advances
2012 · Iain Beehuat Tan, Isabel Ng, et al. · Expert Review of Gastroenterology & Hepatology · 38
A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC.
2013 · Daniel Shao-Weng Tan, Kiat Hon Lim, et al. · Journal of Clinical Oncology · 30
Targeting Treg–fibroblast interaction to enhance immunotherapy in steatotic liver disease-related hepatocellular carcinoma
2025 · Aldo Prawira, Hang Xu, et al. · Gut · 28
Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients
2011 · Wai Meng Tai, Daniel Quah, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 23
Clinicopathologic Characteristics and Survival of Patients with Gastroenteropancreatic Neuroendocrine Neoplasm in a Multi-Ethnic Asian Institution
2018 · Wai Meng Tai, Sze Huey Tan, et al. · Neuroendocrinology · 17
Comparing the Efficacy of Sunitinib with Sorafenib in Xenograft Models of Human Hepatocellular Carcinoma: Mechanistic Explanation
2011 · H. Huynh, S. P. Choo, et al. · Current Cancer Drug Targets · 17
Examining the effects of metformin on survival outcome in stage II/III colorectal cancer patients with diabetes mellitus.
2012 · Guek Eng Lee, Thinzar Aung, et al. · Journal of Clinical Oncology · 11
Case report: Understanding the impact of persistent tissue-localization of SARS-CoV-2 on immune response activity via spatial transcriptomic analysis of two cancer patients with COVID-19 co-morbidity
2022 · Mai Chan Lau, Yang Yi, et al. · Frontiers in Immunology · 9
Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348).
2022 · Ho Yeong Lim, Jeong Heo, et al. · Journal of Clinical Oncology · 8
Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study.
2021 · Changhoon Yoo, Jwa Hoon Kim, et al. · Journal of Clinical Oncology · 7
Do elderly patients benefit from enrollment into Phase I Trials?
2015 · Wai Meng Tai, Cindy Lim, et al. · Journal of Geriatric Oncology · 7
The prognostic impact of KRAS mutation in colorectal cancer patients: A meta-analysis of phase III clinical trials.
2014 · Clarinda Wei Ling Chua, Dawn QQ Chong, et al. · Journal of Clinical Oncology · 5
89 The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma
2021 · Chun Chau Lawrence Cheung, Yong Hock Justin Seah, et al. · Journal for ImmunoTherapy of Cancer · 4
PDF
Outcomes of tyrosine kinase inhibitors after immunotherapy in advanced hepatocellular carcinoma: A multi-center study.
2021 · Thomas Yau, Joycelyn Jie Xin Lee, et al. · Journal of Clinical Oncology · 4
Works count: 45
Citation count: 1,411
H-index: 17
I10-index: 18
Year
Topic
Type